The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - GlaxoSmithKline; MedImmune
Leadership - MedImmune
Stock and Other Ownership Interests - MedImmune
Honoraria - GlaxoSmithKline; MedImmune
Travel, Accommodations, Expenses - GlaxoSmithKline; MedImmune
A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.
 
Mark T. Fleming
Employment - Virginia Oncology Associates
Speakers' Bureau - Genentech; Medivation/Astellas
Travel, Accommodations, Expenses - Genentech; Medivation/Astellas
 
Richard Cathomas
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Honoraria - Astellas Pharma; Bayer; Bellicum Pharmaceuticals; Exelixis; Ferring; Genentech; Johnson & Johnson; Medivation; Merck Serono; Millennium; Pfizer; Progenics; Sanofi
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Astellas Medivation; Dendreon; Endocyte; Genentech; gtx; Johnson & Johnson; Merck; Millennium; Novartis; Oncogenex; progenics; Progenics; Sanofi
Expert Testimony - Celgene; sanofi
Travel, Accommodations, Expenses - Bayer; Bellicum Pharmaceuticals; Celgene; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Oncogenex; Pfizer; Progenics; Sanofi
 
Judy Sing-Zan Wang
No Relationships to Disclose
 
Neil Harrison Bander
Stock and Other Ownership Interests - BZL Biologics
Consulting or Advisory Role - ADC Therapeutics; Avidity Nanomedicines; BZL Biologics; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Cornell University
 
Francesca Zammarchi
Employment - ADC Therapeutics
 
Patrick H. van Berkel
Employment - ADC Therapeutics
Stock and Other Ownership Interests - ADC Therapeutics
Honoraria - ADC Therapeutics
Research Funding - ADC Therapeutics
Patents, Royalties, Other Intellectual Property - ADC Therapeutics
 
Song Hye Cho
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Nairouz Elgeioushi
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca; MedImmune
 
John Bothos
Employment - AstraZeneca; AstraZeneca (I); Johnson & Johnson; Johnson & Johnson (I)
Stock and Other Ownership Interests - AstraZeneca; Pfizer
Travel, Accommodations, Expenses - AstraZeneca (I)
 
Anita Scheuber
No Relationships to Disclose
 
Johann de Bono
Honoraria - AstraZeneca; Genentech; Genmab; GlaxoSmithKline; Merck; Pfizer; Sanofi
Consulting or Advisory Role - AstraZeneca; Genentech; Genmab; GlaxoSmithKline; Merck; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Merck (Inst); Sanofi (Inst)